Axovant Sciences Ltd. lost half of its market value Monday after it said a drug once intended to treat Alzheimer’s disease didn’t meet certain goals in recent studies.
Switzerland-based Axovant, whose shares fell 50% to $2.71 in morning trading, said it would no longer develop its main drug, known as intepirdine, that analysts once thought could top $2 billion in annual sales.
“Based... 